International Journal of Cancer Care and Delivery
Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Efficacy and Safety Outcomes With Meta-Regression
By Mohamed Fawzi Hemida, Fatma A. Rikabe, Amr Khalid Abdallah and 5 others.
Abstract
BackgroundEnfortumab vedotin plus pembrolizumab (EV/P) is a promising treatment for metastatic urothelial carcinoma (mUC), but a comprehensive efficacy and safety synthesis is currently lacking.